Comparing the current results to its competitors, Agios Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 137.75 % year on year. The sales growth was above Agios Pharmaceuticals Inc 's competitors' average revenue growth of 5.44 %, achieved in the same quarter.
Agios Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 54.61 %
Agios Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with numerous large pharmaceutical and biotechnology firms developing or marketing products for the same indications as PYRUKYND®, AQVESME™, and its product candidates. Competitors may introduce products that are more effective, safer, more convenient, or less costly, which could impact the company's market position. Competition also includes major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. The company's focus on rare diseases may increase its exposure to market fluctuations. Its competitive position relies on securing and maintaining patent protection. Additionally, unfavorable pricing regulations or reimbursement practices could adversely affect the business. The pharmaceutical and biotechnology industries are characterized by rapid technological advancements and intense competition centered on proprietary products.
Due to outstanding performance in Overall company, revenue grew by 137.75 % Agios Pharmaceuticals Inc improved its market share, to approximately 0.04 %.
December 18, 2024
: Agios Pharmaceuticals, Inc. announced the positive designation of mitapivat, an oral pyruvate kinase activator, as an orphan medicinal product for the treatment of sickle cell disease by the European Commission. The company’s financial results reflect significant growth and profitability, further establishing its position in the biopharmaceutical sector. In recent developments within the biopharmaceutical landscape, Agios Pharmaceuticals, Inc. has garnered attention for its innovative therapies targeting rare diseases. The recent announcement from the European Commission regarding the designation of mitapivat as an orphan medicinal product for sickle cell disease marks a significant milestone for both ...
August 1, 2024
In recent developments concerning hemolytic anemias, Agios Pharmaceuticals has reported compelling results from multiple Phase 3 clinical studies investigating the therapeutic potential of Mitapivat. This article reviews the findings from the ACTIVATE-KidsT study, focusing on children experiencing pyruvate kinase (PK) deficiency and regularly requiring transfusions, as well as the ENERGIZE-T study, which assessed efficacy in adults with transfusion-dependent thalassemia. The overall safety and efficacy profiles of Mitapivat are discussed, along with implications for future research and treatment approaches in rare blood disorders. Mitapivat, a small molecule PK activator, has emerged as a promising the...
Publicly Traded Peers of Agios Pharmaceuticals Inc
Phathom Pharmaceuticals Inc Share Performance
-4.36%
This Quarter
Phathom Pharmaceuticals Inc
Profile
Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.
180 Life Sciences Corp is a biotechnology company engaged in the research and development of novel drugs that target inflammation and fibrosis to address various diseases such as fibrosis, inflammation, and pain.
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.
Sources:
Agios Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Agios Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
